Skip links

Auto Industry’s COVID-19 Recovery Strategy: Navigating Challenges

Jump To Section

The Novel Corona Virus was a double whammy as it came at a time when the Indian Auto Industry was reeling under the impact of changing emission norms, waning consumer demand and an overall slowdown in the economy.
Indian auto industry COVID19 impact

The Novel Corona Virus was a double whammy as it came at a time when the Indian Auto Industry was reeling under the impact of changing emission norms, waning consumer demand and an overall slowdown in the economy. COVID19 has added to its woes and has decelerated the overall GDP growth forecasts from 5% to a measly 1-2%. However, a strategically planned and concentrated response can help accelerate the recovery and emerge successfully from what can be dubbed the industry’s biggest challenge of the 21st century.

“Plans are worthless, but planning is everything”                                                              –

– Dwight Eisenhower

Indian Auto Industry
Chalking out a strategy for recovery
With various uncertainties looming ahead of the auto industry, the road to recovery depends on 3 R’s:

(i) Reading the signals

(ii) Re-adjust adapting to the new normal and

(iii) Re-prioritise and replan, focusing on innovations that circumvent the challenges posed by the pandemic.

No doubt, new opportunities lie hidden and waiting to be uncovered within this complex environment

1.Smart / Shared Mobility

Stringent lockdown and work from home options had heavily impacted the shared mobility space in the past few months. As businesses open up and people start work, shared mobility could see a potential uptick. Shared mobility will be seen as a cost-effective and safer option compared to crowded public transport. Innovations in integrating health data from various sources into the shared mobility platforms, with the goal of ensuring passenger safety, can further enhance customer confidence and propel the demand for such mobility options, turning this into an opportunity for the Shared Mobility providers.

2.The Phy-gital Experience

March and April 2020 saw an unprecedented fall in sales in the consumer vehicle segment in many brands. However, with lockdown restrictions lifted and customer sentiments improving, demand seems to be picking up now. Demand for vehicles in the lower segments are seeing a steady rise with health concerns being a key driver. For such buyers, the physical retail experience in most dealerships could also seem to be a risk factor.

“Never let a crisis go waste”

– Winston Churchill

As a legacy of COVID19, we are seeing an increased affinity to e-commerce and smart shopping experiences. It is only imperative that the Auto-industry also adopts this digital experience or a more innovative “Phy-gital” experience enabling customer buy in the comfort and safety of their homes complementing the “Physical” touch-points at showrooms. Enabling contactless purchase and seamless digital payments may be the trends of the future in Auto retailing as well.

3.Align with the Digital era

The digital era demands investment into technology innovations and digital transformation of data platforms to help create truly differentiated products and solutions that usher in the potential to drive future growth. The convergence of data from diverse sources like customer data, vehicle data and social data would all add to the dynamics of newer solutions that have the potential to “Wow” the customer. Data is no longer the oil, but the soil on which future innovations can be seeded and game-changing benefits reaped.

4.Innovative engagement models

Ever-increasing cost pressures push companies to look for optimization opportunities and propel them to innovative engagement models which add value to the engagement. Strategic outcome-based partnerships between domain experts and technology practitioners will help companies successfully leverage the post-COVID remote work scenario while also ensuring business continuity along-side employee safety.

Evolution has often been punctuated with such dramatic shifts and the key to surviving these storms lies in the ability to adapt and re-invent ourselves. And I am sure the Indian Auto Industry will bounce back with rigor to emerge a key contender in driving the growth of the nation as a whole.

“It is not the strongest of the species that survives, nor the most intelligent that survives. It is the one that is most adaptable to change.”

Charles Darwin (1809 – 1882)

Picture of Rudhra Mohandoss

Rudhra Mohandoss

Latest Reads


Suggested Reading

Ready to Unlock Your Enterprise's Full Potential?

Adaptive Clinical Trial Designs: Modify trials based on interim results for faster identification of effective drugs.Identify effective drugs faster with data analytics and machine learning algorithms to analyze interim trial results and modify.
Real-World Evidence (RWE) Integration: Supplement trial data with real-world insights for drug effectiveness and safety.Supplement trial data with real-world insights for drug effectiveness and safety.
Biomarker Identification and Validation: Validate biomarkers predicting treatment response for targeted therapies.Utilize bioinformatics and computational biology to validate biomarkers predicting treatment response for targeted therapies.
Collaborative Clinical Research Networks: Establish networks for better patient recruitment and data sharing.Leverage cloud-based platforms and collaborative software to establish networks for better patient recruitment and data sharing.
Master Protocols and Basket Trials: Evaluate multiple drugs in one trial for efficient drug development.Implement electronic data capture systems and digital platforms to efficiently manage and evaluate multiple drugs or drug combinations within a single trial, enabling more streamlined drug development
Remote and Decentralized Trials: Embrace virtual trials for broader patient participation.Embrace telemedicine, virtual monitoring, and digital health tools to conduct remote and decentralized trials, allowing patients to participate from home and reducing the need for frequent in-person visits
Patient-Centric Trials: Design trials with patient needs in mind for better recruitment and retention.Develop patient-centric mobile apps and web portals that provide trial information, virtual support groups, and patient-reported outcome tracking to enhance patient engagement, recruitment, and retention
Regulatory Engagement and Expedited Review Pathways: Engage regulators early for faster approvals.Utilize digital communication tools to engage regulatory agencies early in the drug development process, enabling faster feedback and exploration of expedited review pathways for accelerated approvals
Companion Diagnostics Development: Develop diagnostics for targeted recruitment and personalized treatment.Implement bioinformatics and genomics technologies to develop companion diagnostics that can identify patient subpopulations likely to benefit from the drug, aiding in targeted recruitment and personalized treatment
Data Standardization and Interoperability: Ensure seamless data exchange among research sites.Utilize interoperable electronic health record systems and health data standards to ensure seamless data exchange among different research sites, promoting efficient data aggregation and analysis
Use of AI and Predictive Analytics: Apply AI for drug candidate identification and data analysis.Leverage AI algorithms and predictive analytics to analyze large datasets, identify potential drug candidates, optimize trial designs, and predict treatment outcomes, accelerating the drug development process
R&D Investments: Improve the drug or expand indicationsUtilize computational modelling and simulation techniques to accelerate drug discovery and optimize drug development processes